Protocol Ledger

NCT06847542 · Phase III · RECRUITING

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Interventional Phase III clinical trial protocol NCT06847542 sponsored by Roche / Genentech in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-27 Enrollment: 250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06847542
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06847542
Protocol FieldVerified Registry Value
NCT IdentifierNCT06847542
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment250 participants (ESTIMATED)
Registered Start Date2025-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06847542
Hospital Research SiteLocationSite Profile
Klinikum Chemnitz gGmbHChemnitz, GermanyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI